Not Yet Recruiting
Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.
NCT07339553
- Conditions
- Ovariancancer, Platinum-sensitive Recurrent
- Locations
-
Not specified